Insight by Science
Hospitals can scale penicillin delabeling because patients are already monitored, allowing a protocolized small-dose then full-dose observed challenge to be done safely in many low-risk cases without an allergist present.
Want more like this?
Every card on Korva is an insight someone saved from a podcast or video they loved.
More from this video
See all →A reliable blood test for penicillin allergy is hard to build because allergy-specific antibody levels fall or vary over time and current assays miss many true positives, so single blood panels show low sensitivity.
Aggressive pharmaceutical marketing and regulatory relabeling can inflate perceived allergy prevalence because expanding indications, lobbying, and normalization of rescue products increase diagnoses and prescriptions, which make the condition look more common.
